Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.”
The mean rating for BeiGene stock is 1.64, and its target price is $196.18, implying a potential 60.1% upside based on its December 24 closing price of $122.56.
In comparison, peers Amgen (AMGN), bluebird bio (BLUE), and Incyte (INCY) have received mean ratings of 2.33, 1.96, and 2.24, respectively, and target prices of $204.8, $184.94, and $83.67, respectively, from analysts.
BeiGene’s current ratio, which shows how effectively it can meet its short-term obligations, is 11.60x. In comparison, Amgen’s, bluebird’s, and Incyte’s current ratios are 3.10x, 13.10x, and 4.0x, respectively.
After rising from $97.41 on January 8 to a high of $216.77 on June 8, BeiGene stock corrected to $107.01 on October 29. Since then, after initial buying interest took it to $153.31 on November 30, BeiGene stock has again corrected to its current $122.5 level amid broader market turmoil.
BeiGene’s long-term debt-to-equity ratio is 0.10x, whereas Amgen’s, bluebird’s, and Incyte’s debt-to-equity ratios are 2.05x, 0.08x, and 0.01x, respectively.
BeiGene’s EV (enterprise value) is $5.26 billion, and its EV-to-revenue ratio is 30.23x. Its price-to-sales ratio is 49.02x, and its price-to-book ratio is 3.54x. Amgen’s, bluebird’s, and Incyte’s price-to-book ratios are 8.02x, 2.43x, and 6.90x, respectively.